



The Epidemiology of Multidrug Resistant Microorganisms in Antimicrobial Stewardship Era

Guest Editor:

Dr. Emilio García-Cabrera

Departamento de Medicina
Preventiva y Salud Pública,
Universidad de Sevilla, 41009
Sevilla, Spain

Deadline for manuscript
submissions:

closed (31 December 2022)

Message from the Guest Editor

Antimicrobial resistance emerged as one of the leading public health problems at the end of 20th century and is currently a priority of public health. The World Health Organization, government agencies, and research groups have agreed that this is a global issue and coordinated action plans are needed to stop the spread of AMR. During the first decade of the new millennium, antimicrobial stewardship programs (ASP) appear to be a core element in antimicrobial optimization with a global vision covering issues such as animal use, primary care, and hospitalized care. More than a decade after dissemination and strong implementation of these programs, it is a good time to understand how on a global stage we can change the prevalence and resistance profiles of different pathogens after implementation of ASP.

This Special Issue calls for interventions or observational studies that address changes in the prevalence and resistance profile after ASP implementation. The theme includes studies at the health-system and policy levels; stewardship programs in hospitals, primary care facilities, and pharmacies; and interventions at the community level that cover both human and animal health.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)